Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Vitamin D intake and incidence of multiple sclerosis.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Application of fullerenes in nanomedicine: an update.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Dynamic regulatory network controlling TH17 cell differentiation.
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
4-aminopyridine toxicity: a case report and review of the literature.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
[Nicolau syndrome after administration of glatiramer acetate].
Motor skill learning requires active central myelination.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Rituximab Use in Pediatric Central Demyelinating Disease.

Pages